Development and Validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q)©

Ruiz, Miguel Á.; Pardo, Antonio; Rejas, Javier; Soto, Javier; Villasante, Fernando Vega; Aranguren, José Luis López

doi:10.1111/j.1524-4733.2008.00323.x

Cited by 138 publications

(138 citation statements)

References 35 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…This result is consistent with the preference for the patch over the capsule manifested by caregivers in the preapproval controlled randomized clinical trial of the rivastigmine patch [22], and in a noncomparative cohort study [29]. The mean total score of the SATMED-Q in the transdermal group nearly equaled the norm of the Spanish adult population [27]. All partial scores of the SATMED-Q were also higher with the patch than with the oral formulations.…”

Section: Discussionsupporting

confidence: 76%

“…Activities of daily living refer to functional issues such as personal hygiene or the participation in leisure activities [27]. Consistently, a recent study has shown that high transdermal rivastigmine doses help to preserve patients’ functional integrity without compromising safety or tolerability [31], an aspect that poses a considerable impact on caregiver burden [32].…”

Section: Discussionmentioning

confidence: 80%

“…This self-administered tool was recently developed as a multidimensional, generic instrument for measuring patient satisfaction with chronic drug-based treatments. It has satisfactory psychometric properties [27]. It has 17 items that aggregate into the dimensions of treatment effectiveness, convenience of use, impact on daily activities, medical care, global satisfaction and undesirable side effects.…”

Section: Methodsmentioning

confidence: 99%

“…Partial (dimensions) scores can also be rescaled to the same range. The original publication includes the norms for the Spanish population [27]. Because this instrument is generic and patients were polymedicated, caregivers were asked to focus on anti-dementia (rivastigmine) medication.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer’s Disease Treated with Rivastigmine

Boada

Arranz²

2013

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background and Aims: Poor adherence to anti-dementia drugs is common among patients with Alzheimer’s disease. This study evaluated whether caregivers were more satisfied with, and patients more adherent to, transdermal rivastigmine than oral rivastigmine. Methods: Neurologists, psychiatrists and geriatricians collected sociodemographic and clinical data from 1,078 patients and administered the Treatment Satisfaction with Medicines (SATMED-Q) and the Morisky-Green questionnaires to their caregivers at outpatient consultations. Results: Satisfaction reported was greater with transdermal than oral rivastigmine: mean ± SD of the total SATMED-Q score, 72.5 ± 14.1 vs. 65.2 ± 12.5, p < 0.001. The proportion of adherent patients was greater with transdermal than with oral rivastigmine (65.0 vs. 41.4%, p < 0.001). Satisfaction, in turn, was significantly greater in adherent cases than in nonadherent cases. Conclusions: Facilitating the administration of anti-dementia drugs would improve adherence.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 80%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer’s Disease Treated with Rivastigmine

Boada

Arranz²

2013

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

show abstract

“…Adding questions per ADE on its nature and causality might solve this problem. To assess unknown ADEs of (new) drugs and comparing ADE profiles of different drugs, a generic PRO questionnaire is needed that can measure all possible ADEs [13,15]. Most available patient-reported ADE questionnaires focus on specific ADEs, such as gastrointestinal ADEs [16] or ADEs specific for a drug class, such as inhaled corticosteroids [17] or chemotherapy [18].…”

Section: Introductionmentioning

confidence: 99%

Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire

et al. 2013

View full text Add to dashboard Cite

Background Direct patient reporting of adverse drug events (ADEs) is relevant for the evaluation of drug safety. To collect such data in clinical trials and postmarketing studies, a valid questionnaire is needed that can measure all possible ADEs experienced by patients. Objective Our aim was to develop and test a generic questionnaire to identify ADEs and quantify their nature and causality as reported by patients. Methods We created a draft list of common ADEs in layterms, which were classified in body categories and mapped to the Medical Dictionary for Regulatory Activities (MedDRA Ò ) terminology. Questions about the nature and causality were derived from existing questionnaires and causality scales. Content validity was tested through cognitive debriefing, revising the questionnaire in an iterative process. Feasibility and reliability were assessed using a Web-based version of the questionnaire. Patients received the questionnaire twice. Feasibility was assessed by the reported time needed for completion and ease of use. Reliability was calculated using Cohen's kappa and proportion of positive agreement (PPA) on: (1) any ADE at patient level; (2) similar ADEs at MedDRA Ò System Organ Class level; and (3) the same ADE at ADE-specific level.Results In the development phase, 28 patients with type 2 diabetes or asthma/chronic obstructive pulmonary disease (COPD) participated. Questions and answer options were rephrased, layout was improved, and changes were made in the classification of ADEs. The final questionnaire consisted of 252 ADEs organized in 16 body categories, and included 14 questions per reported ADE. A total of 135 patients using a median of five different drugs completed the Web-based questionnaire twice. The median completion time was 15 min for patients not reporting any ADE, and 30 min for patients reporting at least one ADE. Three quarters of the patients found the questionnaire easy to use. Test-retest reliability was acceptable at patient level (j = 0.50, PPA 0.64) and at MedDRA Ò System Organ Class level (j = 0.52, PPA 0.54), but was low at ADEspecific level (j = 0.38, PPA 0.38). Conclusion We developed a generic patient-reported ADE questionnaire and confirmed its content validity. The questionnaire was feasible and reliable for reporting any ADE and similar ADEs at MedDRA Ò System Organ Class level. Additional work is, however, needed to reliably quantify specific ADEs reported by patients.

show abstract

Patient perspectives

Traulsen,

Krska

2024

Drug Utilization Research

View full text Add to dashboard Cite

Development and Validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q)©

Abstract: The SATMED-Q is a reliable and valid measure of treatment satisfaction, structured in six dimensions, and a summary composite score. Additional work is needed to assess sensitivity to change.

Cited by 138 publications

References 35 publications

Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer’s Disease Treated with Rivastigmine

Transdermal Is Better than Oral: Observational Research of the Satisfaction of Caregivers of Patients with Alzheimer’s Disease Treated with Rivastigmine

Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire

Patient perspectives

Contact Info

Product

Resources

About